Related Experiment Video
Updated: Sep 13, 2025
09:29
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
907
Tracing the Rise of Galectin-3: A Global Bibliometric Insight Into Its Role in Heart Failure
Amjad Bani Hani1, Alaa Tarazi2, Lubna Alnatour2
1General Surgery Department, School of Medicine, The University of Jordan, Amman, Jordan.
International Journal of Vascular Medicine
|August 1, 2025
Summary
This bibliometric analysis reveals a rapid growth in research on galectin-3 as a biomarker for heart failure (HF). Key findings highlight leading countries, institutions, and research trends in understanding galectin-3
Area of Science:
- Cardiology
- Biomarkers
- Bibliometrics
Background:
- Heart failure (HF) presents significant morbidity and mortality.
- Galectin-3 is recognized as a crucial biomarker in HF, linked to cardiac fibrosis and inflammation.
Purpose of the Study:
- To conduct a bibliometric analysis of global scientific output on the association between galectin-3 and heart failure.
- To identify key research trends, influential publications, and collaborative networks in this field.
Main Methods:
- A comprehensive literature search was performed on the Web of Science database.
- Scientometric analysis and visualization were conducted using Microsoft Excel and VOSviewer.
Main Results:
- 705 publications were analyzed, indicating a rapid growth in research on galectin-3 and HF.
- The United States, China, and the Netherlands were the leading contributors. Key authors and institutions were identified.
- Prominent research themes include the relationship between galectin-3 and HF prognosis, fibrosis, and mortality.
Conclusions:
- This is the first bibliometric study on galectin-3 and HF, offering insights into influential research.
- Current research focuses on galectin-3's role in HF diagnosis, pathology, and prognosis.
- Future research should investigate galectin-3 for earlier HF and fibrosis detection, emphasizing international collaboration.
Related Concept Videos
01:26Heart Failure III: Clinical Manifestations
48
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
48
01:29Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
52
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52
01:26Heart Failure Drugs: Inotropic Agents
728
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728
01:30Heart Failure IV: Classification and Diagnostic Evaluation
33
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
33